News & Updates

2026-10-19

Milestone! Sungen Biomed's SGC001 Completes First Patient Enrollment and Dosing in Phase II Clinical Study for Expected Severe Acute Pancreatitis

2026-10-12

Tech Giants Rush into AI Pharma: Experimental Data and Closed-Loop Capabilities Become the Competitive Focus

2026-10-30

Great News! Yugen Pharmaceutical Advances to the National Finals of the First 2026 Biomanufacturing Competition

2026-09-24

Breaking Through the Myocardial Delivery Bottleneck: Small Nucleic Acid Technology Opens a New Era of Precision Treatment for Cardiomyopathy

2026-09-22

The AI Pharmaceutical Industry Ushers in a Window of Rapid Development

2026-09-21

Hotgen Biotech Ranks on the "2026 Beijing Top 100 Private Enterprises in Scientific and Technological Innovation" List

2026-09-18

Youngen Biotech's Next-Generation Small Nucleic Acid Therapy Showcases at BioCon China Expo 2026

2026-09-16

Youngen Biotech Showcases at the 5th BIONNOVA Beijing Innovation Forum, Exploring a New Landscape for Extrahepatic Delivery of Small Nucleic Acid Drugs

2026-09-15

Milestone | Sungen Biomed's Next-Generation Tumor Immunotherapy Backbone Drug SGT003 Completes First Subject Enrollment and Dosing

2026-08-17

YuGen Pharmaceutical's Second-Generation Probiotic Research Progress: Three AKK2645 Studies Published in International Journals

2026-08-03

Sungen Biomedical's SGC001 Approved for Clinical Trial of New Indication: Predicted Severe Acute Pancreatitis

2026-07-27

Youngen Biotechnology: Hotgen Biotech Establishes an AI Pharmaceutical Company to Focus on Small Nucleic Acid Drug R&D